New Heart-Safe combo offers hope for breast cancer patients denied standard care
NCT ID NCT06845319
Summary
This trial is testing a new treatment combination for an aggressive type of breast cancer (triple-negative) in patients who have heart problems and cannot safely receive the usual chemotherapy drugs. The goal is to see if a 12-18 week regimen of three different drugs (carboplatin, paclitaxel, and pembrolizumab) can effectively shrink or eliminate the tumor before surgery. Doctors will use MRI scans during treatment to check how well it's working and adjust the plan if needed.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Medical University of South Carolina
RECRUITINGCharleston, South Carolina, 29425, United States
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.